1619

# WR 0 1 2003 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT CHECKLIST

Client and Matter Name:	CSI 126
Client #/ Matter #:	077044/00004
Attorney and Due Date Pabst	
Check Requested N/A	
I have checked the following sources for references to Supplemental IDS:	
X Application and PTO Correspondence File	APR 0 3 2003 TECH CENTER 1600/2900
Application	APR 0 3 2003
X IDS/ Supp. IDS	IECH CENTER 1600/2000
Office Action/ PTO-892	-0,2900
Other	· · · · · · · · · · · · · · · · · · ·
X PCT File	
PCT Written Opinion	
X International Search Report (partial)	
Other	
Suggestions/Requests for other sources:	
	Erica C. Boughner

ATL1 #570147 v1



## RECEIVED APR 0.3 2003 TECH CENTER 1600/2900 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kai-Uwe Lewandroski and Debra J. Trantolo

Serial No.: 10/054,171 Art Unit: 1619

Filed: January 17, 2002 Examiner: Not Yet Assigned

For: METHODS OF DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS

**Assistant Commissioner for Patents** Washington, D.C. 20231

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449, copies of the four (4) documents cited therein, and a copy of the partial International Search Report, mailed March 6, 2003, in the corresponding PCT application PCT/US02/01566.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1868.

### Certification Under 37 C.F.R. §1.97 (e)(1)

Each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

1

ATL1 #570144 v1

CSI 126 077044/00004 U.S.S.N.: 10/054,171 Filed: January 17, 2002

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

## **Foreign Documents**

<u>Number</u>	Publication Date	<u>Patentee</u>	Country
0 557 663	09-01-1993	Centre de Recherches en	EP
		Rhumatologie	
WO 00/13024	03-09-2000	Medvet Science Pty Ltd.	PCT
WO 00/22437	04-20-2000	Hybritech Incorporated	PCT

### **Publications**

REDDI, et al., "The *Escherichia coli* chaperonin 60 (groEL) is a potent stimulator of osteoclast formation," *J. Bone Min. Res.* 13(8): 1260-1266 (1998).

U.S.S.N.: 10/0

10/054,171

Filed: January 17, 2002 SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has

been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an

independent evaluation of the cited art to determine its relevance to the subject matter of the

present application. Applicants are of the opinion that their claims patentably distinguish over

the art referred to herein, either alone or in combination.

Respectfully submitted,

Patrea L. Pabst

Reg. No. 31,284

Dated: March 28, 2003

HOLLAND & KNIGHT LLP

One Atlantic Center

1201 West Peachtree Street, N.E.

**Suite 2000** 

Atlanta, Georgia 30309-3400

404-817-8473

FAX 404-817-8588

www.hklaw.com

ATLI #570144 vI

3

CSI 126 077044/00004 U.S.S.N.: 10/054,171
Filed: January 17, 2002
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

Erica C. Boughner

Date: March 28, 2003

ATL1 #570144 v1